medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 3

<< Back Next >>

Ann Hepatol 2017; 16 (3)

Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy

Langness JA, Tabano D, Wieland A, Tise S, Pratt L, Ayres HL, Lin S, Ghuschcyan V, Nair KV, Everson GT

Language: English
References: 24
Page: 366-374
PDF size: 163.48 Kb.


ABSTRACT

Introduction. Interferon-free, multi-direct acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection is highly effective and well tolerated, but costly. To gain perspective on the evolving economics of HCV therapy, we compared the cost per cure of a multi-DAA regimen with the prior standard of triple therapy. Material and methods. Patients infected with HCV genotype 1 who were treated through the University of Colorado Hepatology Clinic between May 2011 and December 2014 comprised the study population. The multi-DAA regimen of simeprevir plus sofosbuvir (SMV/SOF) was compared to the triple therapy regimen consisting of peginterferon and ribavirin, with either boceprevir or telaprevir (TT). Sustained-virologic response (SVR) rates, total costs per treatment and adverse events were recorded. Total cost per SVR were compared for the two treatments, controlling for patient demographics and clinical characteristics. Results. One hundred eighty-three patients received SMV/SOF (n = 70) or TT (n = 113). Patients receiving SMV/SOF were older, more treatment experienced, and had a higher stage of fibrosis. SVRs were 86% and 59%, average total costs per patient were $152,775 and $95,943, and average total costs per SVR were $178,237 vs. $161,813.49 for SMV/SOF and TT groups, respectively. Medication costs accounted for 98% of SMV/SOF and 85% of TT treatment costs. Conclusion. The high cure rate of multi-DAA treatment of HCV is offset by the high costs of the DAAs, such that the cost per cure from TT to multi-DAA therapy has been relatively constant. In order to cure more patients, either additional financial resources will need to be allocated to the treatment of HCV or drug costs will need to be reduced.


REFERENCES

  1. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. New Engl J 2009; 360: 1839-50.

  2. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New Engl J 2009; 360: 1827-838.

  3. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New Engl J 2011; 364: 2405-16.

  4. Manns MP, Markova AA, Calle Serrano B, Cornberg M. Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liv Internat 2012; 32(Suppl. 1): 27-31.

  5. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomized study. Lancet 2014; 384: 1756-65.

  6. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New Engl J 2014; 370: 1483-93.

  7. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New Engl J 2014; 370: 1889-98.

  8. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New Engl J 2014; 370: 1879-88.

  9. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomized, phase 2 trial. Lancet 2014; 383: 515-23.

  10. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, Sulkowski MS, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. New Engl J 2014; 370: 1604-14.

  11. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, et al. ABT- 450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. New Engl J 2014; 370: 1973-82.

  12. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients coinfected with HIV-1: a randomized trial. J Am Med Assoc 2015; 313: 1223-31.

  13. Zhou N, Hernandez D, Ueland J, Yang X, Yu F, Sims K, Yin PD, et al. NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection. J Infect Dis 2016; 213: 206-15.

  14. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. J Am Med Assoc 2015; 313: 1736-44.

  15. U.S. Food and Drug Administration News Release: FDA approves Technivie for treatment of chronic hepatitis C genotype 4 [press release]. 2015.

  16. A 4-drug combination (viekira pak) for hepatitis c. J Am Med Assoc 2015; 313(18): 1857-8.

  17. Tungol A, Rademacher K, Schafer JA. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus. JMCP 2011; 17: 685-94.

  18. Gilead's Efforts to Ensure Patient Access to Sovaldi® for Chronic Hepatitis C. Gilead Sciences Policy Position 2014. Available from: https://www.gilead.com/~/media/Files/pdfs/ Policy-Perspectives/PatientAccess-to-SOF-for-HCV-4-28- 14.pdf [Accessed: February 26, 2016].

  19. Issues Document: Hepatitis C Treatment. Emerging Therapeutics 2014. Available from: http://www.medco.com/art/ sam/2014/Issues-Doc-HepC.pdf [Accessed February 26, 2016].

  20. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 2014; 60: 37-45.

  21. Gane EJ SC, Hyland RH, Ding X, Pang PS, Symonds WT, McHutchison JG. ELECTRON: Alloral sofosbuvir-based 12- week regimens for the treatment of chronic HCV genotype 1 infection. 48th Annual Meeting of the European Association for the Study of the Liver; Apr 24-28, 2013; Amsterdam: The Netherlands.

  22. U.S. Food and Drug Administration Approves Gilead's Sovaldi ™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C [press release]. Gilead Sciences, Inc. 2013.

  23. US Department of Veterans Affairs. National Acquisition Center contract catalog search tool. Available from: http:// www.va.gov/nac/index.cfm?template=search_menu [Accessed February 12, 2014].

  24. PharMetrics PlusTM Health Plan Claims Data. 2014. Available from: http://www.imshealth.com/en.




2020     |     www.medigraphic.com